Efficacy of Spravato in Treating Depression in an 86-Year-Old
Author Information
Author(s): Muacevic Alexander, Adler John R, Jivraj Aarman P, Heimer Katherine A, Wukovits Christopher J, Itteera Justin B, Itteera Annupriya
Primary Institution: Hillside TMS (Transcranial Magnetic Stimulation) and Esketamine, New Hyde Park, USA
Hypothesis
Can intranasal esketamine effectively treat treatment-resistant major depressive disorder in elderly patients?
Conclusion
Intranasal esketamine therapy significantly reduced depressive symptoms in an 86-year-old male with treatment-resistant major depressive disorder.
Supporting Evidence
- The patient had a PHQ-9 score of 19 at the start of treatment, indicating severe depression.
- By the 22nd treatment, the patient's PHQ-9 score improved to 1, showing significant symptom reduction.
- The patient reported improved cognitive function and engagement in daily activities after treatment.
Takeaway
This study shows that a special nose spray called Spravato can help an 86-year-old man feel much better from his long-lasting sadness.
Methodology
The patient underwent intranasal esketamine therapy with a four-week induction phase followed by a maintenance phase, with regular assessments using the PHQ-9 scale.
Limitations
The study is based on a single patient case, limiting the generalizability of the findings.
Participant Demographics
An 86-year-old married Caucasian male, retired physician.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website